Figure 3. Cumulative incidence of relapse or progressive
disease
Cumulative incidence of relapse or progressive disease (PD) since the
initiation of IREC therapy: (A) for all patients; (B) according to the
disease status at the beginning of first IREC therapy; (C) according to
the UGT1A1 genotype.
IREC, irinotecan, etoposide, and carboplatin.